Therefore, targeting myostatin with specific monoclonal antibodies may have a therapeutic rationale, as demonstrated by several trials in patients with primitive or secondary myopathies [255,256] and age-related sarcopenia [257]. This evidence concerns the gene MSTN and myopathy.